Severe sporotrichoid fish tank granuloma following infliximab therapy

被引:28
作者
Rallis, Efstathios [1 ]
Koumantaki-Mathioudaki, Elma [2 ]
Frangoulis, Effie [3 ]
Chatziolou, Eftihia [4 ]
Katsambas, Andreas [2 ]
机构
[1] Army Gen Hosp, Dept Dermatol, Athens, Greece
[2] Univ Athens, A Sygros Hosp, Dept Dermatol, Athens, Greece
[3] A Sygros Hosp, Dept Microbiol, Athens, Greece
[4] A Sygros Hosp, Dept Pathol, Athens, Greece
关键词
D O I
10.2165/00128071-200708060-00009
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Mycobacterium marinum is an atypical mycobacterium usually found in non-chlorinated water. It rarely disseminates, except in the setting of a severely immunosuppressed patient, and usually follows a sporotrichotic type of distribution. We report the case of a 45-year-old man who had ankylosing spondylitis and was receiving infliximab and isoniazid for latent tuberculosis. The patient presented with a 5-month history of painful erythematous and suppurative nodules and abscesses on the right upper extremity. M. marinum was not isolated in cultures and histologic findings together with clinical examination provided evidence of sporotrichoid-like fish tank granuloma. The patient was treated with rifampin (rifampicin) and ethambutol for 8 months and responded satisfactorily while continuing to receive infliximab. In accordance with data in the published literature, isoniazid proved ineffective in preventing M. marinum infection in this patient. While mycobacterial complications of tumor necrosis factor-a (TNF alpha) inhibitor therapy are well established, our case appears to be the first reported instance of M. marinum infection in a patient taking infliximab. As antiTNF alpha agents become increasingly used for a variety of conditions, awareness of the potential infectious complications associated with use of these agents will be vital for clinicians.
引用
收藏
页码:385 / 388
页数:4
相关论文
共 20 条
[1]   Retrospective study of Mycobacterium marinum skin infections [J].
Ang, P ;
Rattana-Apiromyakij, N ;
Goh, CL .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2000, 39 (05) :343-347
[2]   Sixty-three cases of Mycobacterium marinum infection -: Clinical features, treatment, and antibiotic susceptibility of causative isolates [J].
Aubry, A ;
Chosidow, O ;
Caumes, E ;
Robert, J ;
Cambau, E .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (15) :1746-1752
[3]   Clinical patterns of cutaneous nontuberculous mycobacterial infections [J].
Bartralot, R ;
García-Patos, V ;
Sitjas, D ;
Rodríguez-Cano, L ;
Mollet, J ;
Martín-Casabona, N ;
Coll, P ;
Castells, A ;
Pujol, RM .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (04) :727-734
[4]   Infection complications associated with the use of biologic agents [J].
Bresnihan, B ;
Cunnane, G .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2003, 29 (01) :185-+
[5]   Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis [J].
Chopra, N ;
Kirschenbaum, AE ;
Widman, D .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2002, 8 (05) :265-268
[6]  
Clegg DO, 2006, J RHEUMATOL, V33, P24
[7]   Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management [J].
Gardam, MA ;
Keystone, EC ;
Menzies, R ;
Manners, S ;
Skamene, E ;
Long, R ;
Vinh, DC .
LANCET INFECTIOUS DISEASES, 2003, 3 (03) :148-155
[8]  
Gbery I P, 1996, Sante, V6, P317
[9]   MYCOBACTERIUM-MARINUM [J].
GLUCKMAN, SJ .
CLINICS IN DERMATOLOGY, 1995, 13 (03) :273-276
[10]  
HARTH M, 1994, J RHEUMATOL, V21, P957